The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug price negotiations under President Donald Trump’s administration. The statement follows criticism from the pharmaceutical industry regarding the program. Suggested Reading Amazon sued for illegally collecting data and tracking location of Californians Starbucks is betting its future on ceramic mugs Trump Media stock pops 7% on crypto expansion plans DeepSeek is a wakeup

Tag-uri: Donald Trump